TC BioPharm (Holdings) plc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of GBP, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Loss before tax
Depreciation
Amortization of intangible assets
Amortization of right of use assets
Share-based payment expense
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization of intangible assets
Write-off intangible assets
Share-based compensation expense
Loss on modification of convertible loan
Change in fair value of convertible loan derivatives
Change in fair value of warrant liability
Change in fair value of other derivative liabilities
Net foreign exchange losses
Finance income
Finance costs
Loss on disposal of tangible assets
Decrease in deferred income
(Increase)/decrease in trade and other receivables
Increase/(decrease) in trade and other payables
Cash used in operations
Interest paid
Interest received
Income tax received / (paid)
Net cash flows used in operating activities
Purchase of property, plant and equipment
Disposal of property, plant and equipment
Purchase of intangible assets
Net cash flows used in investing activities
Repayment of lease liabilities
Receipt from issuance of convertible loan (net of issue costs)
Repayment of convertible loan
Proceeds from sale of warrants
Proceeds received on issue of shares
Share issue costs
Net cash flows from financing activities
Net increase/(decrease) in cash and cash equivalents
Foreign exchange movements on cash and cash equivalents
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year
Change in fair value of derivative liability
Net foreign exchange loss
Noncash interest expense
Loss on disposal of property, plant, and equipment, net
Loss on disposal of property, plant and equipment, net
Changes in operating assets and liabilities:
Change in corporation tax receivable
Change in prepaid expenses and other current assets
Change in operating lease right of use assets
Change in accounts payable and accrued liabilities
Change in lease liabilities
Change in deferred income
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant, and equipment
Disposal of property, plant, and equipment
Purchase of intangible assets
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible loan, net of issuance costs
Repayment of convertible loan
Proceeds from issuance of warrants
Issuance costs in connection with exercise of warrants
Issuance of ordinary shares
Issuance costs in connection with issuance of ordinary shares
Net cash provided by financing activities
Foreign exchange (loss) gain on cash and cash equivalents
NET CHANGE IN CASH
Cash - Beginning of period
Cash - End of period
Supplemental disclosures of non-cash financing activity
Stock dividend

Comments